RxDoctor Payments Data

Lee Arcement, MD

Cardiovascular Disease · Houma, LANPI 1427086248

Payments from drug & device makers

$903in general payments, 2019–2025

Across 51 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$198
  • Novartis$172
  • Boehringer Ingelheim$132
  • Pfizer$126
  • E.r. Squibb & Sons, L.L.C.$64
  • Sunovion Pharmaceuticals Inc.$56
  • plus $154 from 4 others

What the payments were for

  • Food & beverage$72981%
  • Education$17419%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$903 in reported general payments places this provider in the 25th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$40,482
Medicare patients
260
Services billed
617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin184$254,034
EntrestoSacubitril/Valsartan162$222,078
EliquisApixaban149$195,222
XareltoRivaroxaban98$108,551
Praluent PenAlirocumab152$77,176
VascepaIcosapent Ethyl28$21,272
Repatha SureclickEvolocumab30$20,148
FarxigaDapagliflozin Propanediol27$19,671
Ranolazine ErRanolazine136$17,450
Repatha PushtronexEvolocumab15$12,390
Ezetimibe495$7,147
Atorvastatin Calcium951$6,641
Carvedilol811$5,161
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine13$4,338
Eplerenone53$3,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$132$254,034184 claims
NovartisEntresto$172$222,078162 claims
PfizerEliquis$126$195,222149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →